More than 3,300 medical device recalls were recorded in the U.S. in FY2024.
Pharmaceutical quality-related warning letters reached a five-year high in 2024, reflecting increased regulatory enforcement.
U.S. Food and Drug Administration (FDA)
Despite the critical importance of pharmaceutical quality to public health, incidents of failure are steadily increasing due to fragmented supply chains, legacy quality systems, and tighter regulatory scrutiny. Recalls are on the rise, signaling cracks in pharmaceutical quality and compliance frameworks.
As supply networks become more fragmented and geopolitical shifts drive reshoring mandates, operational complexity continues to grow. Tighter regulatory scrutiny and increasing global supply chain dependencies are further compounding the challenge.
This trend stands in contrast to improvements seen in other regulated industries, underscoring the urgent need for more resilient, technology-driven quality frameworks in pharma.
The Hidden Cost of Quality Failures
Quality failures in pharma are not isolated incidents; they have systemic implications across patient safety, regulatory exposure, and business performance. The business impacts of quality failures include:
| Higher Recall Risk |
Generic drugs manufactured in non-advanced economies show 156% higher serious recall rates compared to branded counterparts |
| Regulatory Escalation |
FDA warning letters increased significantly, reflecting stricter enforcement and inspection intensity |
| Supply Disruptions |
Over 220 active drug shortages persist, affecting critical therapies including injectables, antibiotics, and oncology drugs |
| Global Dependency Risk |
Over 80% of pharmaceutical ingredients are sourced offshore, exposing manufacturers to geopolitical disruptions and supply volatility |
| Patient Impact |
With nearly 70% of patients relying on prescription medications, quality failures directly translate into clinical risk and delayed care |
These risks are further amplified by structural factors such as reverse-engineered manufacturing processes and limited incentives for quality differentiation in generic drug markets.
Why Traditional Quality Models Are Breaking Down
Pharmaceutical quality systems have historically been designed around batch-based manufacturing and periodic inspections, a model that is no longer sufficient for complex, globalized supply chains.
Today’s environment is defined by:
- Limited visibility across the global supply chain
- Fragmented quality data across systems
- Reactive compliance frameworks
- Legacy infrastructure unable to support real-time monitoring
The result is a system that identifies issues after they occur, rather than preventing them.
Regulatory Pressure Is Redefining Quality
Regulatory bodies are responding aggressively to rising quality risks, signaling a clear transition from compliance-based oversight to continuous quality assurance. Recent shifts include:
- Expansion of unannounced foreign inspections
- API-focused import alerts and stricter oversight
- Growing emphasis on Quality Management Maturity (QMM)
- Focus on quality culture and continuous improvement
Manufacturers are now expected to demonstrate real-time visibility, proactive risk mitigation, and sustained inspection readiness.
The API Dependency Challenge
One of the most critical structural risks lies in dependency on active pharmaceutical ingredients (APIs). More than 80% of pharmaceutical ingredients are produced overseas, primarily in China and India, with India itself remaining 70–80% dependent on Chinese APIs.
This concentration creates a fragile ecosystem that is vulnerable to geopolitical tensions, regulatory inconsistencies, supply disruptions, and quality variability.
Quality is no longer just a manufacturing function; it is now directly tied to supply chain resilience.
Geopolitics, Tariffs, and the Shift to Resilience
Geopolitical pressures are accelerating a structural shift in pharmaceutical manufacturing.
In 2025, the US imposed significant tariffs on pharmaceutical imports from China, signaling a move to reduce external dependency and strengthen domestic capabilities.
At the same time, Eli Lilly announced a $27 billion investment in US manufacturing, the largest in the industry’s history, with a strong focus on API production and supply chain localization.
These developments reflect a broader industry transition, from cost-driven global sourcing to resilience-driven supply chains, where quality, availability, and control are becoming as critical as cost efficiency.
Drug Shortages: A Symptom of Systemic Fragility
The impact of these structural challenges is already visible. The American Society of Health-System Pharmacists (ASHP) reports that as of March 2026, there are 223 active drug shortages, affecting critical therapies such as injectables, antibiotics, oncology drugs, and IV fluids.
These shortages are not isolated events. They have been caused by:
- Aging manufacturing infrastructure
- Over-reliance on offshore suppliers
- Lack of supply chain transparency
- Economic models favoring low-cost production over resilience
Ensuring quality today requires more than compliance; it demands end-to-end supply visibility and operational resilience.
The Shift to Intelligent Quality Systems
To address these challenges, pharmaceutical organizations are moving toward AI-enabled quality systems. The key technology enablers of this shift are:
| Proactive Risk Detection |
AI models analyze deviations, CAPA data, and audit trails to identify risks before failures occur. |
| Real-Time Quality Monitoring |
Computer vision and sensor-based systems enable continuous monitoring of production parameters. |
| Intelligent Decision Support |
NLP-driven systems analyze unstructured quality data, enabling faster root-cause analysis and corrective actions. |
This evolution marks a transition from reactive to predictive and intelligent quality systems.
Continuous Manufacturing: A Structural Transformation
In addition to adopting AI, the industry is shifting from batch-based to continuous manufacturing models. Continuous manufacturing enables:
- Real-time process control
- Consistent product quality
- Reduced variability
- Faster production cycles
By integrating sensors and analytics, manufacturers gain greater control over critical quality parameters, improving both efficiency and compliance.
Biosimilars: Raising the Quality Benchmark
The rapid growth of biosimilars is further elevating quality expectations. The market reached ~$40 billion in 2025 and is projected to grow significantly over the next decade.
Unlike traditional generics, biosimilars require:
- Extensive clinical validation
- High similarity to reference products
- Strict regulatory compliance
This adds another layer of complexity, requiring advanced quality systems and stronger oversight frameworks.
From Compliance to Competitive Advantage
Quality is no longer just a regulatory requirement; it is becoming a strategic differentiator.
| Organizations that invest in: |
will achieve: |
- AI-driven quality systems
- Continuous manufacturing
- Integrated data ecosystems
- Strong quality culture
|
- Reduced recall risk
- Faster time to market
- Improved supply chain resilience
- Greater patient trust
|
Those relying on legacy systems risk falling behind.
How to Build More Resilient Pharma Quality Systems
The pharmaceutical industry is at a turning point. Rising recalls, global dependencies, regulatory tightening, and geopolitical shifts are collectively reshaping the quality landscape.
The path forward is clear: Quality systems must evolve from reactive compliance frameworks to resilient, intelligence-driven ecosystems that enable real-time decision-making and continuous improvement.
With deep expertise in pharmaceutical quality engineering, digital transformation, AI-led automation, and regulatory compliance, Coforge helps life sciences organizations build future-ready quality systems.
By integrating intelligent monitoring, predictive analytics, and scalable platforms, Coforge enables enterprises to move beyond compliance, toward proactive, resilient quality ecosystems that ensure safety, compliance, and operational excellence at scale.
